What are the key takeaways for Eli Lilly and Co ($LLY)?

Eli Lilly reported Q2 FY2026 revenue of $22,974 million, representing a 47.7% YoY increase driven by accelerated demand for incretin-based therapies. Diluted EPS reached $7.94 for the quarter, reflecting strong operational leverage and a gross margin expansion to 85.8% for the period ended June 30, 2026. Operating cash flow reached $10,690 million for Q2 2026, significantly bolstering liquidity and enabling continued capital expenditure for manufacturing capacity expansions.

Eli Lilly and Co (LLY) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Overview Charts AI Summary Financials Valuation

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Eli Lilly and Company ($LLY)

Eli Lilly and Co (LLY) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $22,974 million with diluted EPS of $7.94 and net income of $7,095 million. Pretax margin was 40.2%, and free cash flow was $4,475 million for the period. The strong financial performance during the quarter was driven primarily by continued high global volume growth and market expansion for incretin-based treatments, notably Mounjaro and Zepbound, alongside robust contributions from established oncology and immunology portfolios. Management highlighted ongoing capital investments directed toward expanding manufacturing capacity to alleviate supply constraints and meet surging international patient demand. Operating expenses increased alongside revenue scaling, reflecting heightened research and development investments aimed at advancing late-stage clinical pipelines in cardiometabolic health, neurodegeneration, and immunology. Liquidity remained sound, enabling robust operational reinvestment while accommodating ongoing share repurchase activity and debt service obligations.

Key Takeaways

1.Eli Lilly reported Q2 FY2026 revenue of $22,974 million, representing a 47.7% YoY increase driven by accelerated demand for incretin-based therapies.
2.Diluted EPS reached $7.94 for the quarter, reflecting strong operational leverage and a gross margin expansion to 85.8% for the period ended June 30, 2026.
3.Operating cash flow reached $10,690 million for Q2 2026, significantly bolstering liquidity and enabling continued capital expenditure for manufacturing capacity expansions.
4.R&D expenses for Q2 2026 totaled $3,819 million, demonstrating management's commitment to advancing late-stage clinical pipelines in obesity, diabetes, and oncology.
5.The company executed $1,601 million in common stock repurchases during the second quarter of fiscal 2026 under its authorized capital return programs.
6.Global supply chain scaling remains a primary operational focus as management works to match unprecedented international prescription volume demand.

What They Do

Eli Lilly and Co discovers, develops, and markets human pharmaceuticals worldwide, operating primarily within a single business segment focused on pharmaceutical products. The company's portfolio targets high-burden therapeutic areas including cardiometabolic diseases (diabetes and obesity), immunology, oncology, and neuroscience, providing life-saving and life-enhancing medicines to millions of patients globally. Customers include wholesale distributors, retail pharmacies, hospitals, clinics, and government healthcare agencies across major geographic markets spanning North America, Europe, Asia, and other international regions. Operating on a massive global scale with tens of thousands of employees, state-of-the-art manufacturing facilities, and extensive R&D complexes, Lilly leverages deep scientific expertise and long-standing clinical research networks. The business model is uniquely differentiated by its proprietary scientific platforms, continuous pipeline innovation, and ability to successfully commercialize blockbuster biologic and small-molecule therapies that address major global health epidemics such as type 2 diabetes and obesity.

How They Make Money

Eli Lilly recognizes revenue primarily from the sale of its pharmaceutical products to third-party wholesale distributors, direct institutional customers, and managed care entities when control of the products transfers to the customer. Revenue is recorded at the net transaction price, accounting for estimated rebates, discounts, returns, and allowances associated with complex healthcare payer agreements. The revenue structure is heavily weighted toward proprietary brand pharmaceutical sales, led by metabolic blockbusters like Mounjaro and Zepbound, alongside established oncology and immunology drugs. While pharmaceutical sales are transactional rather than contractual subscriptions, repeat prescriptions and chronic disease management create predictable, recurring purchasing patterns from patient populations. Revenue growth is principally driven by prescription volume expansion, geographic market penetration for newly launched therapies, pricing mix, and continuous portfolio refreshment through successful clinical development and regulatory approvals.

Competitive Position

Eli Lilly competes globally against major multinational pharmaceutical peers, including Novo Nordisk, Pfizer, Merck, AstraZeneca, and Sanofi, particularly within the fast-growing cardiometabolic and oncology therapeutic spaces. The company's primary competitive advantages stem from its foundational intellectual property, deep proprietary research capabilities, highly specialized biologic manufacturing scale, and well-established global commercial infrastructure. In terms of relative valuation, Lilly commands a premium multiple reflecting its superior top-line growth rate, high profit margins, and dominant market position in obesity and diabetes care relative to historical pharmaceutical industry averages. Financial trends indicate sustained market share gains and formidable pricing power, though competitive threats from alternative metabolic treatments and impending patent expirations require continuous pipeline renewal. While the company enjoys strong barriers to entry due to regulatory hurdles and clinical development costs, competitive pressures from rival drug developers investing heavily in GLP-1 and alternate pathways remain a constant risk to long-term market dominance.

Business Strategy & Moat

Eli Lilly's strategic framework centers on driving organic growth through breakthrough scientific innovation, aggressive clinical pipeline advancement, and continuous global manufacturing expansion. The company possesses a robust intellectual property and intangible asset moat, underpinned by patents, proprietary molecular compounds, and extensive clinical data corpora that create significant barriers to entry for competitors. Switching costs for patients and providers using complex biologic therapies are high, reinforced by clinical efficacy and established treatment regimens. The business flywheel operates through successful R&D yielding blockbuster therapeutics, generating substantial cash flows that are systematically recycled back into advanced clinical trials and massive capital expenditure for manufacturing capacity, which in turn fuels further global market expansion. Capital allocation strategy balances heavy R&D reinvestment and capital expenditures for supply chain infrastructure with disciplined shareholder returns through dividends and share repurchases. Financial metrics, including high gross margins, expanding operating leverage, and robust return on invested capital, confirm that this strategy is strengthening the company's competitive moat over time.

Industry Outlook

The global pharmaceutical industry is experiencing a period of robust growth driven by aging populations, rising chronic disease prevalence, and groundbreaking scientific advances in biologics, precision medicine, and metabolic treatments. Sector growth is heavily influenced by cardiometabolic innovations, oncology advancements, and the expanding role of specialty care pharmaceuticals. Near-term tailwinds include surging patient demand for obesity and diabetes treatments, supportive demographic trends, and accelerating digital health integration into clinical trials. Conversely, headwinds involve increasing pricing scrutiny from government healthcare agencies, patent expirations on older small-molecule drugs, and stringent regulatory approval processes. The regulatory landscape remains complex, with heightened focus on drug pricing, supply chain resilience, and manufacturing quality standards, heavily impacting large-scale multinational pharmaceutical operators like Eli Lilly.

Growth Drivers

•Rapid global adoption and prescription volume expansion of Mounjaro and Zepbound for type 2 diabetes and obesity management.
•Geographic market expansion and regulatory approvals for core metabolic therapies across key international territories.
•Continuous pipeline advancement in late-stage clinical candidates targeting Alzheimer's disease, immunology, and oncology.
•Strategic capital investments in manufacturing infrastructure to scale production capacity and alleviate global supply constraints.
•Favorable product mix shifting toward high-margin proprietary biologic and specialty care therapeutics.

Recent Developments

•Expanded global manufacturing investments throughout the first half of 2026 to increase production capacity for incretin-based medications.
•Reported continued robust quarterly financial results for Q2 2026, demonstrating strong revenue acceleration and net income growth.
•Advanced clinical trial programs across immunology, oncology, and neuroscience portfolios with data readouts during the reporting period.
•Executed active share repurchase programs, utilizing $1,601 million in Q2 2026 to repurchase common stock.
•Navigated ongoing regulatory reviews and label expansion applications for core commercialized drug portfolios across international jurisdictions.

Catalysts

•Upcoming regulatory decisions and label expansion approvals for key cardiometabolic and oncology pipeline candidates over the next 12 months.
•Clinical trial data readouts for late-stage pipeline assets in Alzheimer's disease and immunology expected throughout fiscal 2026.
•Quarterly financial earnings releases tracking the scaling of manufacturing capacity and volume growth of Mounjaro and Zepbound.
•Potential government pricing negotiations and legislative updates affecting pharmaceutical reimbursement frameworks globally.

Share Repurchase / Buyback Program

•During the second quarter of fiscal 2026, the company repurchased $1,601 million of common stock under board-authorized share repurchase programs.

RPO & Key Performance Indicators

•Eli Lilly experienced a year-over-year revenue growth rate of 47.7% in Q2 2026, underscoring strong commercial momentum across its core therapeutic portfolios.

Strengths

•Exceptional top-line revenue growth supported by a 49.58% TTM increase driven by market-leading metabolic therapies.
•Industry-leading gross profit margins consistently exceeding 82-85%, reflecting strong pricing power and product mix efficiency.
•Strong operating cash flow generation, with Q2 2026 operating cash flow reaching $10,690 million, supporting heavy reinvestment.
•Robust intellectual property and patent portfolio safeguarding core blockbuster franchises like Mounjaro and Zepbound.
•High return on invested capital and disciplined R&D spending directed toward high-impact therapeutic categories.

AI Benefits & Opportunities

•Utilization of artificial intelligence and machine learning models to accelerate drug discovery, target identification, and molecular design.
•Deployment of data analytics and predictive modeling to optimize clinical trial design, patient recruitment, and manufacturing supply chain efficiency.

Risks & Concerns for Eli Lilly and Company ($LLY)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Eli Lilly and Company (LLY, filings period ending June 30, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Aug 12, 2026.

Peers of Eli Lilly and Company (LLY)

Eli Lilly and Co (LLY) AI Stock Analysis & Earnings

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.